Bhattacharya · Carcinogenesis 2010 · Preclinical in vitro and orthotopic animal experiment · n=?

Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion.

Cited 95 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical in vitro and animal model research with no human participants

PubMed 20889681 · doi:10.1093/carcin/bgq202 · record verified 2026-08-30

What was done

Investigators evaluated the anticancer activity of allyl isothiocyanate (AITC)-rich mustard seed powder (MSP-1). In vitro, bladder cancer cell lines were exposed to hydrated MSP-1 to test for apoptosis and cell cycle arrest compared to pure sinigrin with myrosinase. In vivo, rats with orthotopically implanted bladder cancer were treated with oral MSP-1 at 71.5 mg/kg (9 μmol/kg sinigrin dose) to assess tumor growth, muscle invasion, and modulation of key therapeutic targets.

What was found

Hydrated MSP-1 induced apoptosis and G(2)/M phase arrest in bladder cancer cell lines via myrosinase-mediated conversion of sinigrin to AITC. In the orthotopic rat bladder cancer model, oral MSP-1 reduced tumor growth by 34.5% (P < 0.05) and blocked muscle invasion by 100%, alongside significant modulation of vascular endothelial growth factor, cyclin B1, and caspase 3.

Why it matters

The findings demonstrate that mustard seed powder effectively delivers bioavailable AITC to bladder tissue, showing potential as a dietary or botanical agent to inhibit bladder cancer progression.

Limits

The study is limited to cell cultures and a rodent model; human clinical efficacy, optimal dosing, and safety are untested. Exact animal sample sizes and variance metrics are not specified in the abstract.

Cited by